Published On: Wed, Nov 25th, 2015

Mylan, Bruised by Failed Perrigo Bid, Set for Face-Off on Assets

Impax, Stada, Taro may be takeover targets for Mylan, Perrigo; Mylan may also look for assets shed in Teva-Allergan deal

(L-R) Robert J Coury,   Mylan and Joseph Papa,   Perrigo

Mylan NV, bruised by its acrimonious and ultimately unsuccessful bid to buy Perrigo Co., is likely to find itself now competing with the drugmaker for other assets.

Both companies may look to buy Impax Laboratories Inc., a generic-drug maker from Hayward, California; Stada Arzneimittel AG, a German maker of off-patent medicines; or Taro Pharmaceutical Industries Ltd. of Israel, said Elizabeth Krutoholow, a Bloomberg Intelligence analyst in New York. All of them have over-the-counter products, making them attractive targets.


Read the full story at Bloomberg, by Makiko Kitamura

Read more about: ,

About the Author

Wordpress site Developed by Fixing WordPress Problems